EHWM
GILD icon

Eads & Heald Wealth Management’s Gilead Sciences GILD Stock Holding History

Eads & Heald Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Sell
3,532
-2,596
-42% -$342K 0.22% 121
2026
Q1 		$854K Buy
+6,128
New +$858K 0.43% 87
2025
Q2 		– Sell
-2,749
Closed -$308K – 139
2025
Q1 		$308K Sell
2,749
-732
-21% -$75.5K 0.16% 122
2024
Q4 		$322K Sell
3,481
-67
-2% -$6.03K 0.16% 121
2024
Q3 		$297K Hold
3,548
– – 0.14% 125
2024
Q2 		$243K Sell
3,548
-299
-8% -$20K 0.12% 132
2024
Q1 		$282K Buy
3,847
+311
+9% +$23.9K 0.13% 126
2023
Q4 		$286K Sell
3,536
-48
-1% -$3.73K 0.14% 125
2023
Q3 		$269K Sell
3,584
-15
-0.4% -$1.15K 0.14% 125
2023
Q2 		$277K Sell
3,599
-106
-3% -$8.45K 0.14% 128
2023
Q1 		$307K Buy
3,705
+375
+11% +$31.1K 0.15% 124
2022
Q4 		$286K Sell
3,330
-1,050
-24% -$83.2K 0.15% 129
2022
Q3 		$270K Buy
4,380
+530
+14% +$33.4K 0.15% 128
2022
Q2 		$238K Buy
+3,850
New +$238K 0.13% 141
2022
Q1 		– Sell
-4,418
Closed -$321K – 149
2021
Q4 		$321K Buy
4,418
+31
+0.7% +$2.13K 0.14% 129
2021
Q3 		$306K Buy
4,387
+1,051
+32% +$73.8K 0.15% 126
2021
Q2 		$230K Buy
3,336
+223
+7% +$14.9K 0.11% 130
2021
Q1 		$201K Buy
+3,113
New +$201K 0.1% 136
2020
Q4 		– Sell
-3,228
Closed -$204K – 133
2020
Q3 		$204K Buy
+3,228
New +$224K 0.12% 124
2016
Q4 		– Sell
-4,460
Closed -$353K – 134
2016
Q3 		$353K Sell
4,460
-2,899
-39% -$235K 0.24% 112
2016
Q2 		$614K Sell
7,359
-138
-2% -$12.2K 0.42% 93
2016
Q1 		$689K Sell
7,497
-110
-1% -$9.92K 0.48% 87
2015
Q4 		$770K Sell
7,607
-550
-7% -$57.2K 0.53% 81
2015
Q3 		$801K Buy
8,157
+419
+5% +$46.5K 0.57% 78
2015
Q2 		$906K Buy
7,738
+4,034
+109% +$441K 0.6% 77
2015
Q1 		$363K Buy
3,704
+880
+31% +$89.4K 0.23% 114
2014
Q4 		$266K Buy
+2,824
New +$292K 0.17% 115

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eads & Heald Wealth Management's GILD Position: Q2 2026 in Review

Eads & Heald Wealth Management reduced its Gilead Sciences (GILD) stake by 42% in Q2 2026, selling an estimated $342K and leaving 3,532 shares worth $446K. The position accounts for 0.22% of the portfolio, ranked #121.

Eads & Heald Wealth Management first reported a position in GILD in Q4 2014 and has held it in 27 quarters since. The position peaked at $906K in Q2 2015. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Eads & Heald Wealth Management held 3,532 shares of Gilead Sciences worth $446K as of Q2 2026.
  • Eads & Heald Wealth Management sold 2,596 Gilead Sciences shares in Q2 2026, an estimated $342K.
  • Gilead Sciences made up 0.22% of Eads & Heald Wealth Management's portfolio in Q2 2026, its #121 holding.
  • Eads & Heald Wealth Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 27 quarters since.
  • Eads & Heald Wealth Management's Gilead Sciences position peaked at $906K in Q2 2015.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Eads & Heald Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.